ArticleFrontiers in oncology2026
Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Introduction: Tricyclic drugs such as chlorpromazine (CPZ), amitriptyline (AmiT), and imipramine (ImiP) have demonstrated antitumorigenic potential, yet their relative potency and selectivity for different tumors remain unclear. Here, we conducted a comparative study of the antitumorigenic effects of these drugs on three major cancer types: breast cancer (MDA-MB-231), neuroblastoma (SH-SY5Y), and melanoma (A375). Methods: Results: In the Discussion: Together, these findings demonstrate clear differences in antitumorigenic potency and cancer-type sensitivity among the tested tricyclic drugs, with CPZ being the most potent in both MDA-MB-231 and SH-SY5Y cells, followed by AmiT and then ImiP, in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.